Depomed Культура компании

Mr. August J. Moretti, also known as Augie, Esq., JD, has been the Chief Financial Officer and Senior Vice President at DepoMed Inc. since January 3, 2012. and serves as its Principal Accounting Officer. Mr. Moretti served as the Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals Inc. (formerly, Alexza Molecular Delivery Corp.) from February 2005 to December 31, 2011 and served as its General Counsel from October 2010 to December 31, 2011. Mr. Moretti served as Secretary of Alexza Pharmaceuticals Inc. from December 2005 to December 31, 2011 and served as its Principal Accounting Officer until May 2010. He served as Chief Financial Officer and General Counsel of Alavita, Inc. ( formerly PPD Biomarker Discovery Sciences LLC and Surromed Inc.) from January 2001 to January 2005. He served at Heller Ehrman LLP. Mr. Moretti is an experienced senior financial executive and expert in securities law whose involvement in the biopharmaceutical industry spans more than three decades. Mr. Moretti has extensive experience with both private and public companies on issues relating to disclosure and public reporting and public and private financings (notably working on IPO / public financings for Cetus, Affymax, Affymetrix, Maxygen, Cepheid, Thoratec, Inhale, Isis and Catalytica). He serves as a Member of Advisory Board of Taraval Associates LLC. He was a Advisor at Taraval Associates Seed Capital Fund L.P. He served as a Member of Heller Ehrman White & McAuliffe LLP, where he represented a number of life science companies, including Affymax and Maxygen from January 1982 to December 2000. Mr. Moretti holds a B.A degree in Economics from Princeton University and a J.D from Harvard Law School.

Mr. Sean P. McKercher has been Senior Vice President of Marketing and Operations at Depomed, Inc. since September 2017. Mr. McKercher has been the President and General Manager of North America at Ipsen S.A. since April 2012. He has over 35 years of leadership experience within the pharmaceutical and biotechnology industries. Mr. McKercher served as Vice President of Commercial Development for North America at Ipsen S.A. from April 16, 2007 to April 2012. Prior to joining Depomed, Mr. McKercher held the position of President and General Manager of Ipsen North America, the U.S. affiliate of Ipsen, a global specialty biopharmaceutical group where he was responsible for creating and implementing regional business strategies. Prior to his seven years at Ipsen, over the course of his fourteen years at Abbott Laboratories, Mr. McKercher served in many leadership roles including Business Unit Manager Specialty Pharmaceuticals Abbott Canada, Commercial Director Pacific/Asia/Africa Region, General Manager South Africa and Region Africa prior to his set of roles in Abbott's US pharmaceutical division. While in the US, Mr. McKercher was General Manager of the Strategic Alliance Franchise, Abbott's $2 billion in sales co-promotion agreement with Boehringer Ingelheim, General Manager for Abbott's leading antibiotic Biaxin and General Manager of Marketing and Sales Operations where he led a team of 200 people in providing support to all of Abbott's U.S. pharmaceutical commercial teams. Mr. McKercher received his M.B.A. with an emphasis in Marketing from Schulich School of Business, York University and a B.Sc. in Kinesiology from the University of Waterloo.

Dr. Santosh J. Vetticaden, M.D., Ph.D., has been the Chief Medical & Scientific Officer and Senior Vice President at Depomed, Inc. since October 18, 2017. Dr. Vetticaden served as an Executive Officer of INSYS Therapeutics, Inc. since April 17, 2017 until April 28, 2017. Dr. Vetticaden served as Interim Chief Executive Officer at INSYS Therapeutics, Inc. since January 09, 2017 until April 17, 2017. Dr. Vetticaden served as the Chief Medical Officer and Senior Vice President of Mast Therapeutics, Inc. since September 2012. Dr. Vetticaden served as the Chief Medical Officer and Senior Vice President of Clinical Development of Cubist Pharmaceuticals Inc. from November 2008 to January 20, 2012, where his tenure was highlighted by successful phase 2 trials and advancing multiple drugs into phase 3. He served as Chief Medical and Development Officer and senior vice president of Cubist Pharmaceuticals Inc. from September 2010 to January 20, 2012 and served as an independent consultant. He has pursued a passion for drug development and commercialization for over 20 years in diverse areas ranging from cardiovascular disease, infectious disease and orphan drug development for hemophilia and pediatric epilepsy. At Cubist, he also played a significant role in the development and execution of new business strategy that resulted in significant product pipeline expansion. Dr. Vetticaden served as Chief Medical Officer and Senior Vice President of Maxygen Inc. from February 21, 2007 to August 15, 2008, where he had responsibilities and oversight for clinical development and regulatory affairs for all of the company's development programs, including Maxy-VIIa, which he progressed from the non-clinical stage through a phase 1 study in hemophilia, resulting in its outlicense to Bayer. and was responsible for its clinical development programs. Dr. Vetticaden has held several senior level positions leading drug development across phase 1 through phase 4 trials at biotech and large pharmaceutical companies. From April 2003 to February 2007, he held senior roles in drug development at Scios, Inc., a subsidiary of Johnson & Johnson, Aventis Pharmaceuticals (now Sanofi) and the Whitehall-Robins Healthcare division of American Home Products Corporation (now Pfizer). Previously, Dr. Vetticaden was employed by subsidiaries of Johnson & Johnson, including Scios, Inc., from April 2003 to February 2007, where he served as Vice President of Clinical Research from April 2003 to August 2006. In this position, Dr. Vetticaden led all of Scios's clinical programs from Phase I through Phase IV, including its marketed drug, Natrecor(R). From 1997 to 2000, he served as Director, Clinical Research, in the Whitehall-Robins Healthcare Division of American Home Products. Prior to his tenure at Scios, Dr. Vetticaden served as Senior Director/Global Project Team Leader for Cardiovascular at Aventis (now Sanofi-Aventis) from June 2000 to April 2003, responsible for Lovenox(R). In his career, from 1986 to 1991, he worked at Biopharmaceutics Research Enterprises /International Drug Registration, Inc. He has more than 22 years of experience as a researcher and medical professional. Dr. Vetticaden has over 25 years of pharmaceutical and biotechnology industry leadership experience. Dr. Vetticaden serves on the board of Heluna Health (formerly Public Health Foundation Enterprises). He served as a Director of Amplyx Pharmaceuticals. He holds an MBA from the Sloan School of Management at the Massachusetts Institute of Technology. He earned his M.D. from the University of Maryland and a Ph.D. in Pharmacokinetics and Pharmacodynamics from Virginia Commonwealth University. Dr. Vetticaden received a B.Pharm. with Honors from Banaras Hindu University in Banaras, India. He completed from 1991 to 1997 a Medical Degree and complete his Residency in Internal Medicine at the Baylor College of Medicine.

Mr. Matthew M. Gosling has been a General Counsel at Depomed Inc. since July 6, 2006 and has been its Senior Vice President since January 2011. Mr. Gosling serves as Secretary at DepoMed Inc. Mr. Gosling served as Vice President at Depomed Inc. since July 6, 2006 until January 2011. Mr. Gosling officially joined Depomed after serving as one of Depomed Inc.'s outside legal counselors for the past several years while he was employed at Heller Ehrman LLP. Mr. Gosling was a partner of Heller Ehrman LLP, where he served a nine-year tenure. At Heller Ehrman, he represented both public and private companies and provided legal counsel on general corporate matters, including SEC compliance and license and collaboration agreements, as well as many other business transactions. Mr. Gosling received his law degree from the University of Chicago and holds a B.A. from the Trinity University, San Antonio.

Dr. Srinivas G. Rao, M.D., Ph.D. has been Chief Medical Officer at Axial Biotherapeutics, Inc. since August 22, 2017. Dr. Rao is a physician-scientist and pharmaceutical executive with over 17 years of professional experience in the pharmaceutical and biotechnology industries. He serves as Chief Scientific Officer at Sova Pharmaceuticals. Dr. Rao is an Advisor to the Simons Foundation Autism Research Initiative. He serves as Clinical Advisor at Avelas BioSciences, Inc. He was the Founder and Chief Executive Officer of Kyalin Biosciences, Inc. He served as the Chief Medical Officer and Senior Vice President of DepoMed Inc. from July 16, 2014 to July 31, 2017. Dr. Rao was the innovator behind milnacipran, launched in the U.S. as Savella' for the treatment of the chronic pain of fibromyalgia in 2009. He served as the Chief Scientific Officer at Cypress Bioscience, Inc. since July 2001 until August 2011 and its Director of Science & Technology since January 2001. Dr. Rao Joined Cypress Bioscience, Inc. in August 2000 and has served in variety of areas, including scientific assessment of potential in-licensing compounds, business development, preclinical study design and development of Cypress' intellectual property programs. At Cypress, Dr. Rao has diverse responsibilities, from business development, to intellectual property and chemistry manufacturing and controls. Moreover, he was responsible for the design and execution for five Phase 2 clinical studies in a range of indications. He serves as a Director of AVACEN, Inc. He served as a Member of Advisory Board at BioMotiv, LLC and also served as its Member of Scientific Advisory Board. Prior to Cypress, Dr. Rao worked as a Free-lance Medical Electronics Consultant. Dr. Rao has published 17 manuscripts with topics ranging from original, basic science and clinical research to invited, topical reviews. His Ph.D. research focused upon central nervous system neuropharmacology and took place in the laboratory of Dr. Patricia Goldman-Rakic. Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. Dr. Rao received his Ph.D. in neurobiology from Yale Graduate School and his M.D. from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School respectively.

Mr. Mark D. Booth, MBA, has been Senior Vice President and General Manager of Specialty Business Unit at Depomed, Inc. since November 2017. Mr. Booth served as the Chief Business Officer and Member of Management Board at Probiodrug AG since March 23, 2016 until August 15, 2016. Mr. Booth served as Consultant of Orexigen Therapeutics, Inc. from October 1, 2015 to April 7, 2016. He served as the Chief Commercial Officer of Orexigen Therapeutics, Inc. from August 2009 to March, 2015. Mr. Booth served as President of Takeda Pharmaceuticals North America Inc. (TPNA) since August 2002 and also served as its Executive Vice President. He has over 30 years of commercial and business development experience. Mr. Booth has a strong history of building brands and businesses over the course of his career and has played an integral role in numerous co-development/co-promotional partnerships that have achieved multi-billion dollar sales status. He held senior leadership positions in sales, operations and product development. Prior to joining TPNA, Mr. Booth served as General Manager and Senior Vice President of Commercial Operations at Immunex Corporation, where he was responsible for sales, marketing and project management. He developed, coordinated and drove strategic execution across clinical, commercial and manufacturing functions. Mr. Booth began his career at Abbott Laboratories in 1983, where he served as Vice President and General Manager for the Anti-Infective/GI franchise, overseeing marketing, sales, late-stage business development and Phase IV development for the franchise. Before leading the Anti-Infective/GI franchise, he rose through the ranks gaining experience in a variety of sales, marketing and managed care positions. He is an active member of the Chicago business community and serves on the Kellogg Biotech Advisory Board. He serves as Member of Advisory Board at Exicure Inc. He serves as a Member of Advisory Board at Aurasense LLC. He serves as a Board Member of the National Pharmaceutical Council and serves as Chairman of iBIO Institute, the educational arm of the Illinois Biotechnology Industry Organization (iBIO). He also serves as a Member of the Founder's Council for Rainbows International, the world's largest charity dedicated to youth grief support. Mr. Booth is a recipient of the Northwestern Alumni Merit Award which is given for high achievements in a profession or field of endeavor. He serves as a Member of the Board of Directors at Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Booth holds a BS in Biology from Northern Illinois University and an MBA from Northwestern University Kellogg School of Management.

Mark Howard serves as the Vice President Information Technology of Depomed, Inc.. Mark started at Depomed, Inc. in Apr of 2007. Mark currently resides in the San Francisco Bay Area.

Steve Greco serves as the Vice President, Sales of Depomed, Inc.. Steve started at Depomed, Inc. in May of 2011. Steve currently resides in the Orange County, California Area.